156_CD GlaxoSmithKline_NNP Taxation_NNP information_NN for_IN shareholders_NNS Information_NN for_IN shareholders_NNS US_NNP shareholders_NNS A_DT summary_NN of_IN the_DT principal_JJ tax_NN consequences_NNS for_IN holders_NNS of_IN The_DT following_NN is_VBZ a_DT summary_NN of_IN certain_JJ United_NNP Kingdom_NNP taxation_NN shares_NNS and_CC ADRs_NNS who_WP are_VBP citizens_NNS or_CC residents_NNS of_IN the_DT United_NNP and_CC United_NNP States_NNPS federal_JJ income_NN tax_NN considerations_NNS that_WDT may_MD be_VB Kingdom_NNP or_CC the_DT United_NNP States_NNPS is_VBZ set_VBN out_RP below_IN ._.
It_PRP is_VBZ not_RB a_DT relevant_JJ to_TO a_DT US_NNP holder_NN of_IN shares_NNS or_CC ADRs_NNS ._.
This_DT summary_NN only_RB complete_JJ analysis_NN of_IN all_PDT the_DT possible_JJ tax_NN consequences_NNS of_IN applies_VBZ to_TO a_DT shareholder_NN that_WDT holds_VBZ shares_NNS or_CC ADRs_NNS as_IN capital_NN purchase_NN or_CC ownership_NN of_IN these_DT securities_NNS ._.
assets_NNS ,_, is_VBZ a_DT citizen_NN or_CC resident_NN of_IN the_DT United_NNP States_NNPS or_CC a_DT domestic_JJ corporation_NN or_CC that_DT is_VBZ otherwise_RB subject_JJ to_TO United_NNP States_NNPS federal_JJ Shareholders_NNS who_WP are_VBP subject_JJ to_TO special_JJ rules_NNS or_CC who_WP are_VBP in_IN any_DT income_NN taxation_NN on_IN a_DT net_JJ income_NN basis_NN in_IN respect_NN of_IN the_DT shares_NNS or_CC doubt_NN about_IN their_PRP$ taxation_NN position_NN should_MD consult_VB their_PRP$ own_JJ ADRs_NNS ,_, and_CC is_VBZ not_RB resident_JJ in_IN the_DT United_NNP Kingdom_NNP for_IN UK_NNP tax_NN professional_JJ advisors_NNS ._.
purposes_NNS and_CC does_VBZ not_RB hold_VB shares_NNS for_IN the_DT purposes_NNS of_IN a_DT trade_NN ,_, The_DT new_JJ UK_NNP US_NNP Income_NNP Tax_NNP Convention_NNP was_VBD signed_VBN on_IN profession_NN or_CC vocation_NN that_WDT is_VBZ carried_VBN on_IN in_IN the_DT United_NNP Kingdom_NNP 24th_JJ July_NNP 2001_CD ._.
However_RB no_DT date_NN has_VBZ yet_RB been_VBN set_VBN for_IN ratification_NN ._.
The_DT statements_NNS regarding_VBG the_DT United_NNP Kingdom_NNP and_CC the_DT United_NNP States_NNPS tax_NN laws_NNS and_CC practices_NNS set_VBN out_RP below_IN are_VBP based_VBN on_IN those_DT Taxation_NNP of_IN dividends_NNS laws_NNS and_CC practices_NNS in_IN force_NN on_IN the_DT date_NN of_IN this_DT report_NN ._.
The_DT gross_JJ amount_NN of_IN dividends_NNS received_VBD including_VBG amounts_NNS in_IN respect_NN of_IN associated_VBN tax_NN credit_NN and_CC UK_NNP withholding_NN tax_NN is_VBZ treated_VBN US_NNP holders_NNS of_IN ADRs_NNS generally_RB will_MD be_VB treated_VBN as_IN the_DT owners_NNS of_IN the_DT as_IN foreign_JJ source_NN dividend_NN income_NN for_IN US_NNP tax_NN purposes_NNS ._.
It_PRP is_VBZ not_RB underlying_VBG shares_NNS for_IN the_DT purposes_NNS of_IN the_DT current_JJ United_NNP eligible_NN for_IN the_DT dividend_NN received_VBN deduction_NN allowed_VBN to_TO US_NNP States_NNPS United_NNP Kingdom_NNP double_JJ taxation_NN conventions_NNS relating_VBG to_TO corporations_NNS ._.
Dividends_NNS on_IN ADRs_NNS are_VBP payable_JJ in_IN US_NNP Dollars_NNPS :_: income_NN and_CC gains_NNS Income_NNP Tax_NNP Convention_NNP ,_, estate_NN and_CC gift_NN taxes_NNS dividends_NNS on_IN shares_NNS are_VBP payable_JJ in_IN pounds_NNS Sterling_NNP ._.
Dividends_NNP Estate_NNP and_CC Gift_NNP Tax_NNP Convention_NNP and_CC for_IN the_DT purposes_NNS of_IN the_DT US_NNP paid_VBD in_IN pounds_NNS Sterling_NNP will_MD be_VB included_VBN in_IN income_NN in_IN the_DT US_NNP Internal_NNP Revenue_NNP Code_NNP of_IN 1986_CD ,_, as_IN amended_VBN the_DT Code_NNP ._.
Dollar_NNP amount_NN calculated_VBN by_IN reference_NN to_TO the_DT exchange_NN rate_NN on_IN The_DT following_VBG analysis_NN deals_NNS with_IN dividends_NNS paid_VBN after_IN the_DT day_NN the_DT dividends_NNS are_VBP received_VBN by_IN the_DT holder_NN ._.
Advance_NNP Corporation_NNP Tax_NNP ACT_NNP was_VBD abolished_VBN for_IN benefits_NNS under_IN the_DT current_JJ income_NN tax_NN convention_NN between_IN for_IN dividends_NNS paid_VBN on_IN or_CC after_IN that_DT date_NN ._.
the_DT United_NNP States_NNPS and_CC the_DT United_NNP Kingdom_NNP ,_, they_PRP may_MD be_VB eligible_JJ ,_, subject_JJ to_TO generally_RB applicable_JJ limitations_NNS ,_, to_TO receive_VB a_DT special_JJ US_NNP UK_NNP shareholders_NNS foreign_JJ tax_NN credit_NN equal_JJ to_TO one-ninth_NN of_IN the_DT amount_NN of_IN cash_NN dividends_NNS that_IN they_PRP receive_VBP on_IN the_DT shares_NNS ,_, so_RB long_RB as_IN they_PRP make_VBP Taxation_NNP of_IN dividends_NNS an_DT election_NN to_TO include_VB in_IN their_PRP$ income_NN ,_, as_IN an_DT additional_JJ notional_NN From_IN 6th_JJ April_NNP 1999_CD ,_, the_DT rate_NN of_IN tax_NN credits_NNS was_VBD reduced_VBN to_TO one_CD dividend_NN ,_, an_DT amount_NN equal_JJ to_TO the_DT tax_NN credit_NN ._.
As_IN a_DT result_NN of_IN compensating_VBG reductions_NNS in_IN the_DT rate_NN of_IN tax_NN tax_NN position_NN will_MD determine_VB whether_IN effective_JJ use_NN can_MD be_VB made_VBN of_IN on_IN dividend_NN income_NN ,_, there_EX is_VBZ no_DT increase_NN in_IN the_DT tax_NN borne_VBN by_IN UK_NNP special_JJ US_NNP foreign_JJ tax_NN credits_NNS against_IN the_DT US_NNP tax_NN liability_NN ._.
Tax_NNP credits_NNS are_VBP ,_, however_RB ,_, no_DT longer_JJR repayable_JJ to_TO shareholders_NNS with_IN a_DT tax_NN liability_NN of_IN less_JJR than_IN From_IN 6th_JJ April_NNP 1999_CD ,_, the_DT rate_NN of_IN tax_NN credits_NNS was_VBD reduced_VBN to_TO one_CD the_DT associated_VBN tax_NN credit_NN ._.
ninth_JJ and_CC ACT_NNP was_VBD abolished_VBN ._.
Consequently_RB ,_, claims_NNS for_IN refunds_NNS of_IN tax_NN credits_NNS on_IN dividends_NNS paid_VBN on_IN or_CC after_IN this_DT date_NN are_VBP now_RB of_IN Taxation_NNP of_IN capital_NN gains_NNS negligible_JJ benefit_NN to_TO US_NNP shareholders_NNS ._.
UK_NNP shareholders_NNS may_MD be_VB liable_JJ for_IN UK_NNP tax_NN on_IN gains_NNS on_IN the_DT disposal_NN of_IN shares_NNS or_CC ADRs_NNS ._.
They_PRP may_MD also_RB be_VB entitled_VBN to_TO Taxation_NNP of_IN capital_NN gains_NNS indexation_NN relief_NN and_CC taper_VB relief_NN on_IN such_JJ sales_NNS ._.
Indexation_NN relief_NN is_VBZ Generally_RB ,_, US_NNP holders_NNS will_MD not_RB be_VB subject_JJ to_TO UK_NNP capital_NN gains_NNS tax_NN ,_, calculated_VBN on_IN the_DT market_NN value_NN of_IN shares_NNS at_IN 31st_CD March_NNP 1982_CD and_CC but_CC will_MD be_VB subject_JJ to_TO US_NNP tax_NN on_IN capital_NN gains_NNS realized_VBN on_IN the_DT sale_NN on_IN the_DT cost_NN of_IN any_DT subsequent_JJ purchases_NNS from_IN the_DT date_NN of_IN such_JJ or_CC other_JJ disposal_NN of_IN shares_NNS or_CC ADRs_NNS ._.
Indexation_NN relief_NN for_IN individual_JJ shareholders_NNS ceased_VBD on_IN Estate_NNP and_CC gift_NN taxes_NNS 5th_JJ April_NNP 1998_CD ._.
Taper_VB relief_NN is_VBZ available_JJ to_TO individual_JJ shareholders_NNS Under_IN the_DT Estate_NNP and_CC Gift_NNP Tax_NNP Convention_NNP ,_, a_DT US_NNP shareholder_NN is_VBZ who_WP hold_VBP or_CC are_VBP deemed_VBN to_TO hold_VB shares_NNS for_IN at_IN least_JJS three_CD years_NNS not_RB generally_RB subject_JJ to_TO UK_NNP inheritance_NN tax_NN ._.
Inheritance_NN tax_NN Stamp_NNP duty_NN Individual_NNP shareholders_NNS may_MD be_VB liable_JJ to_TO inheritance_NN tax_NN on_IN the_DT UK_NNP stamp_NN duty_NN or_CC ,_, as_IN the_DT case_NN may_MD be_VB ,_, SDRT_NNP will_MD ,_, subject_JJ to_TO transfer_VB of_IN shares_NNS or_CC ADRs_NNS ._.
This_DT tax_NN may_MD be_VB charged_VBN on_IN the_DT certain_JJ exemptions_NNS ,_, be_VB payable_JJ on_IN any_DT issue_NN or_CC transfer_NN of_IN shares_NNS amount_NN by_IN which_WDT the_DT value_NN of_IN the_DT shareholder_NN 's_POS estate_NN is_VBZ reduced_VBN to_TO the_DT ADR_NNP custodian_NN or_CC depository_NN at_IN a_DT rate_NN of_IN 1.5_CD per_IN cent_NN of_IN as_IN a_DT result_NN of_IN any_DT transfer_NN by_IN way_NN of_IN gift_NN or_CC other_JJ disposal_NN at_IN less_JJR their_PRP$ price_NN if_IN issued_VBN ,_, the_DT amount_NN of_IN any_DT consideration_NN provided_VBD than_IN full_JJ market_NN value_NN ._.
Exceptionally_RB ,_, such_PDT a_DT gift_NN or_CC other_JJ disposal_NN if_IN transferred_VBN on_IN sale_NN ,_, or_CC their_PRP$ value_NN if_IN transferred_VBN for_IN no_DT is_VBZ subject_JJ to_TO both_DT UK_NNP inheritance_NN tax_NN and_CC US_NNP estate_NN or_CC gift_NN tax_NN ._.
The_DT Estate_NNP and_CC Gift_NNP Tax_NNP Convention_NNP would_MD generally_RB provide_VB for_IN No_DT SDRT_NN would_MD be_VB payable_JJ on_IN the_DT transfer_NN of_IN an_DT ADR_NNP ._.
No_DT UK_NNP tax_NN paid_VBN in_IN the_DT United_NNP States_NNPS to_TO be_VB credited_VBN against_IN tax_NN payable_JJ in_IN stamp_NN duty_NN should_MD be_VB payable_JJ on_IN the_DT transfer_NN of_IN an_DT ADR_NNP provided_VBD the_DT United_NNP Kingdom_NNP ._.
that_IN the_DT instrument_NN of_IN transfer_NN is_VBZ executed_VBN and_CC remains_VBZ at_IN all_DT times_NNS outside_IN the_DT UK_NNP ._.
Any_DT stamp_NN duty_NN on_IN the_DT transfer_NN of_IN an_DT ADR_NNP Stamp_NNP duty_NN would_MD be_VB payable_JJ at_IN a_DT rate_NN of_IN 0.5_CD per_IN cent_NN of_IN the_DT consideration_NN UK_NNP stamp_VB duty_NN or_CC ,_, as_IN the_DT case_NN may_MD be_VB ,_, stamp_VB duty_NN reserve_NN tax_NN for_IN the_DT transfer_NN ._.
Any_DT sale_NN of_IN the_DT underlying_JJ shares_NNS would_MD result_VB in_IN SDRT_NNP will_MD ,_, subject_JJ to_TO certain_JJ exemptions_NNS ,_, be_VB payable_JJ on_IN the_DT liability_NN to_TO UK_NNP stamp_VB duty_NN or_CC ,_, as_IN the_DT case_NN may_MD be_VB ,_, SDRT_NNP at_IN a_DT rate_NN purchase_NN of_IN shares_NNS at_IN a_DT rate_NN of_IN 0.5_CD per_IN cent_NN of_IN the_DT purchase_NN price_NN ._.
There_EX is_VBZ a_DT minimum_JJ charge_NN of_IN 5_CD where_WRB a_DT stamp_NN There_EX is_VBZ a_DT minimum_JJ charge_NN of_IN 5_CD where_WRB a_DT stamp_NN duty_NN liability_NN duty_NN liability_NN arises_VBZ ._.
GlaxoSmithKline_NNP 157_CD Cross_NNP reference_NN to_TO Form_NN 20-F_NN This_DT table_NN has_VBZ been_VBN provided_VBN as_IN a_DT cross_NN reference_NN from_IN the_DT information_NN included_VBD in_IN this_DT Annual_JJ Report_NNP to_TO the_DT requirements_NNS of_IN Form_NN 20-F_NN ._.
Item_NN Page_NNP Item_NNP Page_NNP 1_CD Identity_NN of_IN directors_NNS ,_, senior_JJ management_NN and_CC advisors_NNS n_VBP a_DT 8_CD Financial_NNP information_NN A_DT Consolidated_NNP statements_NNS and_CC other_JJ financial_JJ information_NN 2_CD Offer_NN statistics_NNS and_CC expected_VBN timetable_NN n_NN a_DT Financial_NNP statements_NNS See_VB Item_NNP 18_CD 3_CD Key_NNP information_NN Legal_NNP proceedings_NNS 103-107_CD A_DT Selected_VBN financial_JJ data_NNS 71_CD B_NNP Significant_JJ changes_NNS n_VBP a_DT D_NNP Risk_NNP factors_NNS 64-65_CD 9_CD The_DT offer_NN and_CC listing_NN 4_CD Information_NN on_IN the_DT company_NN A_DT Share_NN price_NN history_NN 154_CD A_DT History_NN and_CC development_NN of_IN the_DT company_NN 06_CD C_NNP Markets_NNPS 154_CD B_NNP Business_NNP overview_VBD 10_CD Additional_JJ information_NN Products_NNP 07-09_CD B_NNP Memorandum_NNP and_CC Articles_NNPS of_IN Association_NNP Footnote_NNP i_FW Competition_NNP 10-11_CD C_NNP Material_NNP contracts_NNS n_VBP a_DT Regulation_NN 11-12_CD D_NNP Exchange_NNP controls_VBZ 155_CD Marketing_NNP and_CC distribution_NN 13_CD E_NNP Taxation_NNP 156_CD Manufacture_NNP and_CC supply_NN 13-14_CD H_NNP Documents_NNS on_IN display_NN 38_CD Research_NNP and_CC development_NN 14-22_CD Intellectual_NNP property_NN 23_CD 11_CD Quantitative_JJ and_CC qualitative_JJ disclosures_NNS about_IN market_NN risk_NN Information_NN technology_NN 24_CD Treasury_NNP policies_NNS 62-63_CD Environment_NNP ,_, health_NN and_CC safety_NN 26_CD Note_NN 32_CD -_: Financial_NNP instruments_NNS and_CC related_VBN disclosures_NNS 110-113_CD Access_NNP to_TO medicines_NNS in_IN the_DT developing_VBG world_NN 27_CD 12_CD Description_NN of_IN securities_NNS other_JJ than_IN equity_NN securities_NNS n_VBP a_DT Global_JJ community_NN partnerships_NNS 27-29_JJ 13_CD Defaults_NNS ,_, dividend_NN arrearages_NNS and_CC delinquencies_NNS n_VBP a_DT C_NNP Organisational_NNP structure_NN 139-141_CD 14_CD Material_NNP modifications_NNS to_TO the_DT rights_NNS of_IN security_NN holders_NNS D_NNP Property_NNP ,_, plant_NN and_CC equipment_NN 25_CD and_CC use_NN of_IN proceeds_NNS n_VBP a_DT Environmental_JJ responsibility_NN 26_CD Note_NN 6_CD Segment_NN information_NN 86-88_CD 15_CD Controls_NNP and_CC procedures_NNS 35-38_CD Note_NN 17_CD Tangible_JJ fixed_JJ assets_NNS 96_CD 16_CD Reserved_VBN 5_CD Operating_NN and_CC financial_JJ review_NN and_CC prospects_NNS 17_CD Financial_NNP statements_NNS n_VBP a_DT A_DT Operating_NN results_NNS 18_CD Financial_NNP statements_NNS 2002_CD and_CC 2001_CD 53-65_CD Directors_NNS statements_NNS of_IN responsibility_NN 74_CD 2001_CD and_CC 2000_CD 66-70_CD Independent_NNP auditors_NNS report_VBP 75_CD Under_IN US_NNP accounting_NN principles_NNS 72_CD Consolidated_NNP statement_NN of_IN profit_NN and_CC loss_NN 76-77_CD B_NNP Liquidity_NN and_CC capital_NN resources_NNS 60-65_CD Consolidated_NNP statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS 76-77_CD C_NNP Research_NNP and_CC development_NN ,_, patents_NNS and_CC licenses_NNS ,_, etc._FW ._.
14-22_CD ,52_CD Consolidated_NNP statement_NN of_IN cash_NN flow_NN 78-79_CD D_NNP Trend_NNP information_NN 52_CD Consolidated_NNP balance_NN sheet_NN 80_CD 6_CD Directors_NNS ,_, senior_JJ management_NN and_CC employees_NNS Reconciliation_NNP of_IN movements_NNS in_IN equity_NN shareholders_NNS funds_NNS 80_CD A_DT Directors_NNS and_CC senior_JJ management_NN 32-33_CD Company_NN balance_NN sheet_NN 81_CD B_NNP Compensation_NNP Notes_NNP to_TO the_DT financial_JJ statements_NNS 82-141_CD Remuneration_NNP report_NN 39-50_CD 19_CD Exhibits_NNS C_NNP Board_NNP practices_NNS Corporate_JJ governance_NN 34-38_CD Footnote_NNP i_FW D_NNP Employees_NNP Information_NNP responsive_JJ to_TO this_DT item_NN is_VBZ incorporated_VBN by_IN reference_NN GlaxoSmithKline_NNP people_NNS 24-25_CD to_TO Memorandum_NNP and_CC Articles_NNPS of_IN Association_NNP of_IN GlaxoSmithKline_NNP Note_VB 33_CD Employee_NN costs_NNS 114-118_CD at_IN pages_NNS 3536_CD of_IN the_DT Groups_NNS Annual_JJ Report_NNP on_IN Form_NN 20-F_NN for_IN Financial_NNP record_NN 142-150_CD the_DT year_NN ended_VBD 31st_CD December_NNP 2000_CD ._.
E_NNP Share_NNP ownership_NN GlaxoSmithKline_NNP people_NNS 24-25_JJ Note_NN 34_CD Employee_NN share_NN schemes_NNS 118-121_CD Share_NN options_NNS 48_CD Incentive_NN plans_NNS 49_CD Directors_NNS interests_NNS 47,50_CD 7_CD Major_JJ shareholders_NNS and_CC related_VBN party_NN transactions_NNS A_DT Major_JJ shareholders_NNS 155_CD B_NNP Related_VBN party_NN transactions_NNS 38,121_CD
